Sensyne Health plc (SSYNF)
Sensyne Health plc operates in the Medical - Healthcare Information Services industry of the Healthcare sector, headquartered in Oxford, GB. The stock last traded at $0.00, down 96.08% on the session, giving a market capitalisation of $33,293. On trailing twelve-month figures it carries a trailing P/E of -0.02, a net margin of -302.6%. Its beta of 1.70 implies it has historically moved more than the broad market.
Sensyne Health plc, an Oxford, UK-headquartered company founded in 2018, is a prominent healthcare technology provider. It develops innovative software solutions that facilitate connections between medical practitioners and patients throughout the United Kingdom and the United States. The company’s diverse product portfolio encompasses digital tools for patient monitoring and management, diagnostic analysis, and advanced AI algorithms. Key offerings for patient care include web-based applications like CVm-Health for COVID-19 self-monitoring, DBm-Health for clinician-supervised diabetes management, and BPm-Health for pregnant women to self-monitor blood pressure. Prescribed digital therapeutics are also prominent, such as GDm-Health for remote gestational diabetes management, EDGE for at-home chronic obstructive pulmonary disease (COPD) monitoring, and Support-HF for remote heart failure monitoring. Beyond direct patient interfaces, Sensyne Health provides MagnifEye for reading and analyzing diagnostic tests, SEND as an evidence-based digital charting system for vital signs, and CleanSpace for tracking personal air pollution exposure. Its technological backbone includes the Sense clinical AI algorithm engine, alongside specialized algorithms like SYNE-COV for predicting COVID-19 patient outcomes and SYNE-OPS for real-time operational patient management. Sensyne Health actively collaborates with various organizations across the healthcare and research sectors. It maintains strategic research alliances with leading pharmaceutical firms such as Bayer and Roche. Further research collaborations include an agreement with Alexion to investigate patient prevalence and outcomes in specific disease areas, and a partnership with Bristol Myers Squibb focused on applying machine learning to rare blood disease research. Academic ties are evident through its research agreement with the University of Oxford for a multi-omics drug discovery project in asthma. Additionally, the company holds strategic research agreements with several NHS Trusts, including Milton Keynes University Hospital, Somerset, Hampshire, Royal Wolverhampton, and Royal Devon and Exeter.
Sensyne Health plc is most often compared with the following Healthcare names: